Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, August 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 122 articles:
HTML format


 

Single Articles

  1. MA Y, Luo W, Bunch BL, Pratt RN, et al
    1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p.
    Oncotarget. 2017 Jul 27. doi: 10.18632/oncotarget.19629.
    Abstract    

    Abstract available

  2. SHI HB, Yu JX, Yu JX, Feng Z, et al
    Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles.
    World J Surg Oncol. 2017;15:147.
    Abstract    

    Abstract available

  3. ZHU J, Li Y, Chen C, Ma J, et al
    NF-kappaB p65 Overexpression Promotes Bladder Cancer Cell Migration via FBW7-Mediated Degradation of RhoGDIalpha Protein.
    Neoplasia. 2017;19:672-683.
    Abstract    

    Abstract available

  4. LIU H, Chang JK, Hou JQ, Zhao ZH, et al
    Inhibition of miR-221 influences bladder cancer cell proliferation and apoptosis.
    Eur Rev Med Pharmacol Sci. 2017;21:3193-3199.
    Abstract    

    Abstract available

  5. GERACE C, Montorsi F, Tambaro R, Carteni G, et al
    Cost of illness of urothelial bladder cancer in Italy.
    Clinicoecon Outcomes Res. 2017;9:433-442.
    Abstract    

    Abstract available

  6. LOFTFIELD E, Freedman ND, Inoue-Choi M, Graubard BI, et al
    A Prospective Investigation of Coffee Drinking and Bladder Cancer Incidence in the United States.
    Epidemiology. 2017;28:685-693.
    Abstract    

    Abstract available

  7. AZEVEDO R, Peixoto A, Gaiteiro C, Fernandes E, et al
    Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
    Oncotarget. 2017 Jul 21. doi: 10.18632/oncotarget.19433.
    Abstract    

    Abstract available

  8. CHENG TC, Din ZH, Su JH, Wu YJ, et al
    Sinulariolide Suppresses Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase through the PI3K/AKT/mTOR Signaling Pathway in Human Bladder Cancer Cells.
    Mar Drugs. 2017;15.
    Abstract    

    Abstract available

  9. SAHU D, Lotan Y, Wittmann B, Neri B, et al
    Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
    Cancer Med. 2017 Aug 1. doi: 10.1002/cam4.1109.
    Abstract    

    Abstract available

  10. RACHAKONDA T, Kendall B, Spivak AM, Boltax J, et al
    Pleural Effusion Caused by Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer.
    Open Forum Infect Dis. 2017;4:ofx126.
    Abstract    

    Abstract available

  11. YOON HJ, Yoo J, Kim Y, Lee DH, et al
    Enhanced Application of 18F-FDG PET/CT in Bladder Cancer by Adding Early Dynamic Acquisition to a Standard Delayed PET Protocol.
    Clin Nucl Med. 2017 Jul 29. doi: 10.1097/RLU.0000000000001780.
    Abstract    

    Abstract available

  12. HU R, Zhong P, Xiong L, Duan L, et al
    Long Noncoding RNA Cancer Susceptibility Candidate 8 Suppresses the Proliferation of Bladder Cancer Cells via Regulating Glycolysis.
    DNA Cell Biol. 2017 Jul 31. doi: 10.1089/dna.2017.3785.
    Abstract    

    Abstract available

  13. HUANG SY, Chang SF, Liao KF, Chiu SC, et al
    Tanshinone IIA Inhibits Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Modulation of STAT3-CCL2 Signaling.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  14. PAVAN GRANDHI TS, Potta T, Nitiyanandan R, Deshpande I, et al
    Chemomechanically engineered 3D organotypic platforms of bladder cancer dormancy and reactivation.
    Biomaterials. 2017;142:171-185.
    Abstract    

    Abstract available

  15. PACKIAM VT, Lamm DL, Barocas DA, Trainer A, et al
    An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
    Urol Oncol. 2017 Jul 26. pii: S1078-1439(17)30350.
    Abstract    

    Abstract available

  16. NECCHI A, Mariani L, Lo Vullo S, Yu EY, et al
    Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
    Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125.
    Abstract    

    Abstract available

  17. NECCHI A, Pond GR, Smaldone MC, Pal SK, et al
    Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
    Eur Urol Focus. 2017 Mar 31. pii: S2405-4569(17)30079.
    Abstract    

    Abstract available

  18. NASELLI A, Hurle R, Paparella S, Buffi NM, et al
    Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2017 Jan 13. pii: S2405-4569(17)30006.
    Abstract    

    Abstract available

  19. KUKREJA JB, Porten S, Golla V, Ho PL, et al
    Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Eur Urol Focus. 2017 Jan 18. pii: S2405-4569(16)30181.
    Abstract    

    Abstract available

  20. KRAMER MW, Altieri V, Hurle R, Lusuardi L, et al
    Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer: Update 2016.
    Eur Urol Focus. 2017 Jan 11. pii: S2405-4569(16)30180.
    Abstract    

    Abstract available

  21. VIND-KEZUNOVIC S, Bouchelouche K, Ipsen P, Hoyer S, et al
    Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up.
    Eur Urol Focus. 2017 Jun 23. pii: S2405-4569(17)30156.
    Abstract    

    Abstract available

  22. DRAY EV, Cameron AP
    Identifying Patients with High-Risk Neurogenic Bladder: Beyond Detrusor Leak Point Pressure.
    Urol Clin North Am. 2017;44:441-452.
    Abstract    

    Abstract available

  23. KRISHNAMURTHY A, Jimeno A
    Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
    Drugs Today (Barc). 2017;53:217-237.
    Abstract    

    Abstract available

  24. MUSAYEV T
    [ORTHOTOPIC URINE DERIVATION AFTER RADICAL CYSTECTOMY (REVIEW)].
    Georgian Med News. 2017;:29-35.
    Abstract    

    Abstract available

  25. XING NZ, Kang N, Song LM, Niu YN, et al
    Laparoscopic radical cystectomy with novel orthotopic neobladder with bilateral isoperistaltic afferent limbs: initial experience.
    Int Braz J Urol. 2017;43:57-66.
    Abstract    

    Abstract available

  26. SEDAGHAT S, Gheytanchi E, Asgari M, Roudi R, et al
    Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas.
    Appl Immunohistochem Mol Morphol. 2017;25:196-202.
    Abstract    

    Abstract available

  27. YAN L, Li Q, Yang J, Qiao B, et al
    TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion and tumor growth of bladder cancer.
    J Cell Biochem. 2017 Aug 11. doi: 10.1002/jcb.26340.
    Abstract    

    Abstract available

  28. FAIREY AS, Jacobsen NE
    Taking it to the HILT: High-intensity local treatment with radical cystectomy for metastatic bladder cancer.
    Can Urol Assoc J. 2017;11:249-250.
    Abstract    



  29. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.
    J Oncol Pract. 2017 Aug 10:JOP2017024919. doi: 10.1200/JOP.2017.024919.
    Abstract    



  30. CHEN Z, Zhou L, Wang L, Kazobinka G, et al
    HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/beta-catenin signaling.
    Mol Carcinog. 2017 Aug 10. doi: 10.1002/mc.22715.
    Abstract    

    Abstract available

  31. LI Y, Zheng F, Xiao X, Xie F, et al
    CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells.
    EMBO Rep. 2017 Aug 9. pii: e201643581. doi: 10.15252/embr.201643581.
    Abstract    

    Abstract available

  32. JIN H, Xie Q, Guo X, Xu J, et al
    p63alpha protein upregulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wasf3/Wave3/MMP9 signaling and bladder cancer invasion.
    J Biol Chem. 2017 Aug 9. pii: jbc.M117.792010. doi: 10.1074/jbc.M117.792010.
    Abstract    

    Abstract available

  33. ZHU F, Qian W, Zhang H, Liang Y, et al
    SOX2 Is a Marker for Stem-like Tumor Cells in Bladder Cancer.
    Stem Cell Reports. 2017;9:429-437.
    Abstract    

    Abstract available

  34. GAO L, Li SH, Tian YX, Zhu QQ, et al
    Role of downregulated miR-133a-3p expression in bladder cancer: a bioinformatics study.
    Onco Targets Ther. 2017;10:3667-3683.
    Abstract    

    Abstract available

  35. CAO W, Tian J, Li C, Gao Y, et al
    A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
    Virol J. 2017;14:149.
    Abstract    

    Abstract available

  36. COLLARILE P, Bidoli E, Barbone F, Zanier L, et al
    Residence in Proximity of a Coal-Oil-Fired Thermal Power Plant and Risk of Lung and Bladder Cancer in North-Eastern Italy. A Population-Based Study: 1995-2009.
    Int J Environ Res Public Health. 2017;14.
    Abstract    

    Abstract available

  37. GARAPATI SS, Hadjiiski L, Cha KH, Chan HP, et al
    Urinary Bladder Cancer Staging in CT Urography using Machine Learning.
    Med Phys. 2017 Aug 8. doi: 10.1002/mp.12510.
    Abstract    

    Abstract available

  38. SIDAWAY P
    Bladder cancer: PPARgamma-RXRalpha alterations promote immune evasion.
    Nat Rev Urol. 2017 Aug 8. doi: 10.1038/nrurol.2017.
    Abstract    



  39. GUHANIYOGI R
    Bayesian nonparametric areal wombling for small-scale maps with an application to urinary bladder cancer data from Connecticut.
    Stat Med. 2017 Aug 7. doi: 10.1002/sim.7408.
    Abstract    

    Abstract available

  40. XIA J, Zeng M, Zhu H, Chen X, et al
    Emerging role of Hippo signalling pathway in bladder cancer.
    J Cell Mol Med. 2017 Aug 7. doi: 10.1111/jcmm.13293.
    Abstract    

    Abstract available

  41. AVIRMED S, Wang BS, Selenge B, Sanjaajamts A, et al
    Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population.
    Mol Clin Oncol. 2017;7:412-420.
    Abstract    

    Abstract available

  42. KANG HW, Seo SP, Jeong P, Ha YS, et al
    Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer.
    Oncol Lett. 2017;14:2468-2474.
    Abstract    

    Abstract available

  43. WU H, Hao A, Cui H, Wu W, et al
    TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer.
    Oncol Lett. 2017;14:2432-2438.
    Abstract    

    Abstract available

  44. LI S, Wang F, Zhai Z, Fu S, et al
    Synergistic effect of bladder cancer-specific oncolytic adenovirus in combination with chemotherapy.
    Oncol Lett. 2017;14:2081-2088.
    Abstract    

    Abstract available

  45. TRUTA A, Popon TAH, Saraci G, Ghervan L, et al
    Health Related Quality of life in bladder cancer. Current approach and future perspectives.
    Clujul Med. 2017;90:262-267.
    Abstract    

    Abstract available

  46. HADKHALE K, MacLeod J, Demers PA, Martinsen JI, et al
    Occupational variation in incidence of bladder cancer: a comparison of population-representative cohorts from Nordic countries and Canada.
    BMJ Open. 2017;7:e016538.
    Abstract    

    Abstract available

  47. MIAO X, Gao H, Liu S, Chen M, et al
    Down-regulation of microRNA-224 -inhibites growth and epithelial-to-mesenchymal transition phenotype -via modulating SUFU expression in bladder cancer cells.
    Int J Biol Macromol. 2017 Aug 2. pii: S0141-8130(17)30303.
    Abstract    

    Abstract available

  48. LV M, Zhong Z, Huang M, Tian Q, et al
    lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA.
    Biochim Biophys Acta. 2017;1864:1887-1899.
    Abstract    

    Abstract available

  49. SIDDIQUI MR, Grant C, Sanford T, Agarwal PK, et al
    Current clinical trials in non-muscle invasive bladder cancer.
    Urol Oncol. 2017;35:516-527.
    Abstract    

    Abstract available

  50. STAPF M, Teichgraber U, Hilger I
    Methotrexate-coupled nanoparticles and magnetic nanochemothermia for the relapse-free treatment of T24 bladder tumors.
    Int J Nanomedicine. 2017;12:2793-2811.
    Abstract    

    Abstract available

  51. D'ANDREA D, Moschini M, Gust KM, Abufaraj M, et al
    Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy.
    J Surg Oncol. 2017;115:455-461.
    Abstract    

    Abstract available

  52. PARK S, Kang SY, Kwon GY, Kwon JE, et al
    Clinicopathologic Characteristics and Mutational Status of Succinate Dehydrogenase Genes in Paraganglioma of the Urinary Bladder: A Multi-Institutional Korean Study.
    Arch Pathol Lab Med. 2017;141:671-677.
    Abstract    

    Abstract available

  53. WANG F, Wu LM, Hua XL, Zhao ZZ, et al
    Intravoxel incoherent motion diffusion-weighted imaging in assessing bladder cancer invasiveness and cell proliferation.
    J Magn Reson Imaging. 2017 Aug 17. doi: 10.1002/jmri.25839.
    Abstract    

    Abstract available

  54. WANG Y, Zhang H, Li X, Chen W, et al
    Differential expression profile analysis of lncRNA UCA1alpha regulated mRNAs in bladder cancer.
    J Cell Biochem. 2017 Aug 16. doi: 10.1002/jcb.26345.
    Abstract    

    Abstract available

  55. GECIT I, Eryilmaz R, Kavak S, Meral I, et al
    The Prolidase Activity, Oxidative Stress, and Nitric Oxide Levels of Bladder Tissues with or Without Tumor in Patients with Bladder Cancer.
    J Membr Biol. 2017 Aug 16. doi: 10.1007/s00232-017-9971.
    Abstract    

    Abstract available

  56. LOPEZ-BELTRAN A, Cheng L, Montorsi F, Scarpelli M, et al
    Concomitant bladder cancer and prostate cancer: challenges and controversies.
    Nat Rev Urol. 2017 Aug 16. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  57. THOMA C
    Bladder cancer: The promise of liquid biopsy ctDNA analysis.
    Nat Rev Urol. 2017 Aug 16. doi: 10.1038/nrurol.2017.
    Abstract    



  58. AVITAN O, Bahouth Z, Halachmi S, Shprits S, et al
    Histopathologic Differences between Jewish and Arab Population in Israel at First-Time Presentation with Bladder Cancer.
    Biomed Res Int. 2017;2017:8239601.
    Abstract    

    Abstract available

  59. VERMA A, Kapoor R, Mittal RD
    Genetic Variation in CD166 Gene and Its Association with Bladder Cancer Risk in North Indian Population.
    Indian J Clin Biochem. 2017;32:292-300.
    Abstract    

    Abstract available

  60. HUSSEIN S, Mosaad H, Rashed HE, Ahmed S, et al
    Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features.
    Mol Biol Rep. 2017 Aug 14. doi: 10.1007/s11033-017-4118.
    Abstract    

    Abstract available

  61. CORMIO A, Sanguedolce F, Musicco C, Pesce V, et al
    Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets.
    Crit Rev Oncol Hematol. 2017;117:67-72.
    Abstract    

    Abstract available

  62. MASTRANGELO G, Carta A, Arici C, Pavanello S, et al
    An etiologic prediction model incorporating biomarkers to predict the bladder cancer risk associated with occupational exposure to aromatic amines: a pilot study.
    J Occup Med Toxicol. 2017;12:23.
    Abstract    

    Abstract available

  63. FEKI-TOUNSI M, Khlifi R, Louati I, Fourati M, et al
    Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population.
    Environ Sci Pollut Res Int. 2017 Aug 12. doi: 10.1007/s11356-017-9767.
    Abstract    

    Abstract available

  64. OUGHTON JB, Poad H, Twiddy M, Collinson M, et al
    Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.
    BMJ Open. 2017;7:e017913.
    Abstract    

    Abstract available

  65. STEINBERG RL, Nepple KG, Velaer KN, Thomas LJ, et al
    Quadruple immunotherapy of Bacillus Calmette-Guerin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Urol Oncol. 2017 Aug 8. pii: S1078-1439(17)30386.
    Abstract    

    Abstract available

  66. LEE Y, Kischuk E, Crist S, Ratliff TL, et al
    Targeting and Internalization of Liposomes by Bladder Tumor Cells Using a Fibronectin Attachment Protein-Derived Peptide-Lipopolymer Conjugate.
    Bioconjug Chem. 2017;28:1481-1490.
    Abstract    

    Abstract available

  67. GERULLIS H, Ecke TH, Barski D, Bantel C, et al
    Retrospective analysis of a surgical innovation using the IDEAL framework: radical cystectomy with epidural anaesthesia.
    J Int Med Res. 2017;45:714-722.
    Abstract    

    Abstract available

  68. SHIGETA K, Kikuchi E, Hagiwara M, Ando T, et al
    Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma.
    Surg Oncol. 2017;26:73-79.
    Abstract    

    Abstract available

  69. NISHIOKA K, Shimizu S, Shinohara N, Ito YM, et al
    Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers.
    Radiat Oncol. 2017;12:44.
    Abstract    

    Abstract available

  70. KRENGLI M, Pisani C, Deantonio L, Surico D, et al
    Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers.
    Radiat Oncol. 2017;12:18.
    Abstract    

    Abstract available

  71. ROIFE D, Kang Y, Wang L, Fang B, et al
    Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.
    Surgery. 2017;161:1246-1254.
    Abstract    

    Abstract available

  72. ZHUANG J, Shen L, Yang L, Huang X, et al
    TGFbeta1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer.
    Theranostics. 2017;7:3053-3067.
    Abstract    

    Abstract available

  73. PAN Y, Chang T, Marcq G, Liu C, et al
    In vivo biodistribution and toxicity of intravesical administration of quantum dots for optical molecular imaging of bladder cancer.
    Sci Rep. 2017;7:9309.
    Abstract    

    Abstract available

  74. MIYAKE M, Morizawa Y, Hori S, Tatsumi Y, et al
    Diagnostic and prognostic role of urinary collagens in primary human bladder cancer.
    Cancer Sci. 2017 Aug 24. doi: 10.1111/cas.13384.
    Abstract    

    Abstract available

  75. YUAN GJ, Chen X, Lu J, Feng ZH, et al
    CBX8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway.
    Cancer Sci. 2017 Aug 24. doi: 10.1111/cas.13383.
    Abstract    

    Abstract available

  76. LI J, Xu X, Meng S, Liang Z, et al
    MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial-mesenchymal transition progression in bladder cancer.
    Cell Death Dis. 2017;8:e3010.
    Abstract    

    Abstract available

  77. DILIZIA EM, Sadeghi F
    Surgical and pathological outcomes of robotic-assisted radical cystectomy for bladder cancer in the community setting.
    J Robot Surg. 2017 Aug 23. doi: 10.1007/s11701-017-0740.
    Abstract    

    Abstract available

  78. REN H, Tang P, Zhao Q, Ren G, et al
    Symptom clusters and related factors in bladder cancer patients three months after radical cystectomy.
    BMC Urol. 2017;17:65.
    Abstract    

    Abstract available

  79. BOEGEMANN M, Aydin AM, Bagrodia A, Krabbe LM, et al
    Prospects and progress of immunotherapy for bladder cancer.
    Expert Opin Biol Ther. 2017 Aug 23:1-15. doi: 10.1080/14712598.2017.1366445.
    Abstract    

    Abstract available

  80. LIANG LG, Sheng YF, Zhou S, Inci F, et al
    An Integrated Double-Filtration Microfluidic Device for Detection of Extracellular Vesicles from Urine for Bladder Cancer Diagnosis.
    Methods Mol Biol. 2017;1660:355-364.
    Abstract    

    Abstract available

  81. HUO J, Chu Y, Chamie K, Smaldone MC, et al
    Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.
    Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30215.
    Abstract    

    Abstract available

  82. MOSSANEN M, Kibel AS, Goldman RH
    Exploring exposure to Agent Orange and increased mortality due to bladder cancer.
    Urol Oncol. 2017 Aug 17. pii: S1078-1439(17)30392.
    Abstract    

    Abstract available

  83. FLAIG TW, Kamat AM, Hansel D, Ingersoll MA, et al
    Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium.
    Bladder Cancer. 2017;3:211-223.
    Abstract    

    Abstract available

  84. YANG X, Su LJ, La Rosa FG, Smith EE, et al
    The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model.
    Bladder Cancer. 2017;3:201-210.
    Abstract    

    Abstract available

  85. KATES M, Chappidi MR, Brant A, Milbar N, et al
    High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer.
    Bladder Cancer. 2017;3:191-199.
    Abstract    

    Abstract available

  86. SUI W, Lim EA, Joel Decastro G, McKiernan JM, et al
    Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy.
    Bladder Cancer. 2017;3:181-189.
    Abstract    

    Abstract available

  87. BREYER J, Shalekenov S, Aziz A, van Rhijn BWG, et al
    Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer.
    Bladder Cancer. 2017;3:173-180.
    Abstract    

    Abstract available

  88. LI R, Sylvester R, Dinney CP, Kamat AM, et al
    Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.
    Bladder Cancer. 2017;3:147-148.
    Abstract    



  89. KAMAT AM, Lerner S, Black P, Bellmunt J, et al
    Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.
    Bladder Cancer. 2017;3:145-146.
    Abstract    



  90. MIRSAIDI N, Burns MP, McClain SA, Forsyth E, et al
    Enhanced Mortality to Metastatic Bladder Cancer Cell Line MB49 in Vasoactive Intestinal Peptide Gene Knockout Mice.
    Front Endocrinol (Lausanne). 2017;8:162.
    Abstract    

    Abstract available

  91. LIU J, Duan X
    PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells.
    Cancer Cell Int. 2017;17:76.
    Abstract    

    Abstract available

  92. PICHLER R, Tulchiner G, Fritz J, Schaefer G, et al
    Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Int J Med Sci. 2017;14:811-819.
    Abstract    

    Abstract available

  93. CHA KH, Hadjiiski L, Chan HP, Weizer AZ, et al
    Bladder Cancer Treatment Response Assessment in CT using Radiomics with Deep-Learning.
    Sci Rep. 2017;7:8738.
    Abstract    

    Abstract available

  94. WU Z, Wang S, Jiang F, Li Q, et al
    Erratum to "Mass spectrometric detection combined with bioinformatic analysis identified possible protein markers and key pathways associated with bladder cancer" [Gene 626C (2017) 407-413].
    Gene. 2017 Aug 15. pii: S0378-1119(17)30624-8. doi: 10.1016/j.gene.2017.
    Abstract    



  95. CAO R, Wang G, Qian K, Chen L, et al
    Silencing of HJURP induces dysregulation of cell cycle and ROS metabolism in bladder cancer cells via PPARgamma-SIRT1 feedback loop.
    J Cancer. 2017;8:2282-2295.
    Abstract    

    Abstract available

  96. CHEN W, Luo K, Ke Z, Kuai B, et al
    TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling.
    J Cancer. 2017;8:1892-1899.
    Abstract    

    Abstract available

  97. HUANG CP, Chen CC, Shyr CR
    The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer.
    Cytotherapy. 2017 Aug 14. pii: S1465-3249(17)30633.
    Abstract    

    Abstract available

  98. YANG Z, Yang X, Lu X, Gao L, et al
    Primary malignant mesenchymoma of bladder: Case report and review of the literature.
    Medicine (Baltimore). 2017;96:e7579.
    Abstract    

    Abstract available

  99. RICKMAN DS, Beltran H, Demichelis F, Rubin MA, et al
    Biology and evolution of poorly differentiated neuroendocrine tumors.
    Nat Med. 2017;23:1-10.
    Abstract    

    Abstract available

  100. DAL MORO F, Haber GP, Wiklund P, Canda AE, et al
    Robotic intracorporeal urinary diversion: practical review of current surgical techniques.
    Minerva Urol Nefrol. 2017;69:14-25.
    Abstract    

    Abstract available

  101. AUTENRIETH ME, Horn T, Kurtz F, Nguyen K, et al
    [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
    Urologe A. 2017;56:40-43.
    Abstract    

    Abstract available

  102. HANLEY KZ, Cohen C, Osunkoya AO
    Hepatocyte Nuclear Factor-1beta Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall.
    Appl Immunohistochem Mol Morphol. 2017;25:134-138.
    Abstract    

    Abstract available

  103. GUSTAFSON TL, Kitchell BE, Biller B
    Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival.
    Vet Comp Oncol. 2017;15:174-183.
    Abstract    

    Abstract available

  104. ZHOU HH, Liu LY, Yu GH, Qu GM, et al
    Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
    Anticancer Res. 2017;37:4529-4537.
    Abstract    

    Abstract available

  105. DU P, Wang S, Tang X, An C, et al
    Reduced Expression of Metastasis Suppressor-1 (MTSS1) Accelerates Progression of Human Bladder Uroepithelium Cell Carcinoma.
    Anticancer Res. 2017;37:4499-4505.
    Abstract    

    Abstract available

  106. DUDDERIDGE T
    Positive messages for bladder cancer management in negative sentinel lymph node study.
    BJU Int. 2017;120:302-303.
    Abstract    



  107. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    Abstract    

    Abstract available

  108. WEN T, Yang Z, He L, Lin K, et al
    The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0882.2017.
    Abstract    

    Abstract available

  109. VANDEKERKHOVE GR, Todenhofer T, Annala M, Struss WJ, et al
    <span style="font-weight: 400;">Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer</span>.
    Clin Cancer Res. 2017 Jul 31. pii: clincanres.1140.2017.
    Abstract    

    Abstract available

  110. KATES M, Date A, Yoshida T, Afzal U, et al
    Preclincial Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.1082.2017.
    Abstract    

    Abstract available

  111. ZENG S, Zhu Y, Ma AH, Yu W, et al
    The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.0033.2017.
    Abstract    

    Abstract available

  112. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    Abstract    

    Abstract available

  113. SUN Y, Guan Z, Zhao W, Jiang Y, et al
    Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-kappaB signal-dependent and signal-independent manner.
    Int J Oncol. 2017 Aug 2. doi: 10.3892/ijo.2017.4089.
    Abstract    

    Abstract available

  114. SONG W, Jeon HG, Jeong BC, Seo SI, et al
    Clinical significance of incidentally detected bladder wall thickening on computed tomography.
    Int Urol Nephrol. 2017;49:191-196.
    Abstract    

    Abstract available

  115. GONDO T, Ohno Y, Nakashima J, Hashimoto T, et al
    Preoperative determinant of early postoperative renal function following radical cystectomy and intestinal urinary diversion.
    Int Urol Nephrol. 2017;49:233-238.
    Abstract    

    Abstract available

  116. SHORE ND, Boorjian SA, Canter DJ, Ogan K, et al
    Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Clin Oncol. 2017 Aug 23:JCO2017723064. doi: 10.1200/JCO.2017.72.3064.
    Abstract    

    Abstract available

  117. BALAR AV
    Immune Checkpoint Blockade in Metastatic Urothelial Cancer.
    J Clin Oncol. 2017;35:2109-2112.
    Abstract    

    Abstract available

  118. CHANG SS
    Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation.
    J Urol. 2017;198:482-483.
    Abstract    



  119. CHANG SS
    Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    J Urol. 2017;198:482-483.
    Abstract    



  120. GAO SL, Kong CZ, Zhang Z, Li ZL, et al
    TRPM7 is overexpressed in bladder cancer and promotes proliferation, migration, invasion and tumor growth.
    Oncol Rep. 2017 Aug 7. doi: 10.3892/or.2017.5883.
    Abstract    

    Abstract available

  121. MARIAPPAN P, Lavin V, Phua CQ, Khan SAA, et al
    Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers - a Prospective Double-Blind Clinical Study.
    Urology. 2017 Aug 14. pii: S0090-4295(17)30802.
    Abstract    

    Abstract available

  122. SU YL, Hsieh MC, Chiang PH, Sung MT, et al
    Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.
    PLoS One. 2017;12:e0169657.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;